Development of ELISAs in the context of a vaccine program against Candida albicans

Background of Elisa Based assays model development

• In addition to viruses and bacteria, fungi are the other organisms, that are either equally or more dangerous to human health.

  

• Vaccines against invasive pathogens represent a major step forward in combating infectious diseases.
• There is an increasing interest in developing safe and potent immune-based therapeutics to tackle fungal diseases. In this context, vaccine design and its development have a priority.

Objectives of the model

• To develop customized ELISAs to quantify antibodies specific for 5 different antigens used as vaccine candidates against Candida albicans.

Our approach at Vibiosphen

• Exhaustive state of the art of the different experimental parameters that required to be optimized for the development of the assay
• Optimization of each parameter
• Update our client after each step of the optimization
• Use of the developed ELISAs to screen successive vaccination campaigns
• Rapid results delivery: priority mission for two members of the company to perform the tests

Outcomes of Elisa Based assays model

• Determination of antibodies titers specific for 5 different antigens in serums of immunized mice, rabbits and rats.
• This brought insights into the most promising vaccination regimens which were then used for the design of the further campaign vaccinations.
• The vaccine program entered phase I clinical trial.